Skip to content
    AMGN
    Earnings call· Dec 2025(Q4 FY25)

    AMGEN Q4 FY25 earnings call AMGN

    Feb 3, 2026 Source

    Executive summary

    Amgen Q4 FY25 — Strong Portfolio Performance and Pipeline Momentum

    Amgen concluded FY25 with robust operational performance, driven by double-digit growth in revenues and EPS, and 14 products achieving blockbuster status. The company is entering 2026 with momentum from key growth drivers and a deep pipeline, particularly in cardiometabolic and rare diseases, while navigating anticipated biosimilar competition and regulatory dialogues for certain products. Management remains confident in its ability to deliver sustained long-term growth and value.

    Highlights

    5
    • Amgen delivered double-digit growth in revenues and EPS for 2025, with 14 products achieving blockbuster status (>$1 billion in sales).

    • 13 products delivered double-digit sales growth and 18 products achieved record results in 2025.

    • Repatha sales grew 36% year-over-year to surpass $3 billion in 2025, driven by growing urgency to treat patients.

    • The biosimilars portfolio delivered strong growth, increasing 37% to $3 billion in 2025.

    • Generated $8.1 billion in free cash flow for the full year 2025, reflecting operational momentum and rigorous working capital management.

    Concerns

    5
    • Prolia is expected to experience accelerated sales erosion in 2026 due to increased biosimilar competition.

    • Otezla sales are expected to erode in 2026 due to unfavorable pricing in the U.S. and generic launches in the EU.

    • The FDA requested a voluntary withdrawal of TAVNEOS on January 16, 2026, due to concerns over the re-adjudication process for 9 patients in the ADVOCATE study.

    • Q1 2026 total company revenues are expected to see lower mid-single-digit year-over-year growth, partly due to a ~$250 million inventory build in Q4 2025 and seasonal headwinds.

    • Anticipated declines in 2026 from increased denosumab biosimilar competition, price declines for certain other products, and continued increases in 340B program utilization.

    Guidance & targets

    11
    CategoryTargetConfidence
    Full-year 2026 total revenues
    $37.0 billion to $38.4 billion
    high materiality
    High
    Full-year 2026 non-GAAP earnings per share
    $21.60 to $23
    high materiality
    High
    Full-year 2026 non-GAAP operating margin as a percentage of product sales
    roughly 45% to 46%
    medium materiality
    High
    Full-year 2026 other revenue
    $1.6 billion to $1.8 billion
    medium materiality
    High
    Full-year 2026 non-GAAP R&D expense growth
    low single digits
    medium materiality
    High
    Full-year 2026 non-GAAP other income and expense
    $2.3 billion to $2.4 billion
    medium materiality
    High
    Full-year 2026 non-GAAP tax rate
    16% to 17.5%
    medium materiality
    High
    2026 share repurchases
    not to exceed $3 billion
    high materiality
    High
    2026 capital expenditures
    about $2.6 billion
    medium materiality
    High
    Q1 2026 total company revenues growth
    lower mid-single-digit year-over-year growth
    medium materiality
    High
    Q1 2026 non-GAAP operating margin
    lowest of the year and roughly the same as Q4 of 2025
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Rare disease portfolio
    The rare disease portfolio demonstrated strong performance across its products, with significant growth from UPLIZNA and TAVNEOS.
    UPLIZNA sales: $655 millionUPLIZNA growth: 73% year-over-yearTEPEZZA sales: $1.9 billionTEPEZZA growth: 3% year-over-yearTAVNEOS sales: $459 millionTAVNEOS growth: 62% year-over-year
    $5.2 billion14%
    Innovative oncology portfolio
    Growth was driven by BiTE medicines, with IMDELLTRA and BLINCYTO being key contributors.
    IMDELLTRA sales: $627 millionBLINCYTO sales: $1.5 billionBLINCYTO growth: 28% year-over-year
    $8.7 billion11%
    Biosimilars portfolio
    The biosimilars portfolio provided meaningful top-line growth and broad patient access, with PAVBLU gaining momentum.
    PAVBLU sales: $700 million
    $3 billion37%

    Operational metrics

    14
    Non-GAAP operating margin
    46%
    FY25

    This is the non-GAAP operating margin for the full fiscal year 2025.

    Non-GAAP R&D spending growth
    22%year-over-year
    FY25

    This increase reflects spending on an unprecedented number of opportunities in the late-stage pipeline.

    Incremental R&D spending from business development
    $300 million
    Q3-Q4 2025

    This spending resulted from several business development transactions closed in the third and fourth quarters of 2025.

    Debt retired
    $6 billion
    2025

    Amgen strengthened its balance sheet by retiring this amount of debt.

    Non-GAAP tax rate
    15.9%1.4 percentage points year-over-year increase
    FY25

    The increase was primarily due to changes in earnings mix.

    Dividend payments per share
    $2.386% increase compared to 2024
    Q4

    This represents the dividend payment per share in the fourth quarter.

    Inventory build
    $250 million
    Q4 2025

    This inventory build could potentially impact first quarter 2026 sales.

    UPLIZNA IgG4-related disease diagnosed population
    35,000
    current

    This is the estimated diagnosed population for IgG4-related disease in the U.S.

    TAVNEOS prescribers
    4,000
    since launch

    This number represents the health care professionals who have prescribed TAVNEOS since its launch.

    IMDELLTRA US sites administering
    1,600
    current

    The majority of doses are provided in the community setting.

    Blockbuster products
    14
    2025

    This number of products achieved sales of $1 billion or more in 2025.

    Double-digit sales growth products
    13
    2025

    This number of products delivered double-digit sales growth year-over-year in 2025.

    Record sales products
    18
    2025

    This number of products achieved record sales results for Amgen in 2025.

    Biosimilars portfolio cumulative sales
    $13 billion
    since 2018

    This is the total sales contribution from the biosimilars portfolio since the launch of the first medicine in 2018.

    Industry KPIs

    11
    MetricValueDetails
    Capital deployment
    Launch access metrics
    Patent cliff loe bridge
    Pipeline read out calendar
    Product franchise net sales
    Lead franchise concentration
    Regulatory approvals filings
    Therapeutic drug market share
    Prescription volume new starts
    Clinical trial efficacy safety data
    Cumulative patients uptake since launch

    Deals & partnerships

    2
    Kyowa Kirindivestiture

    Amgen terminated the development and commercialization collaboration for rocatinlimab, returning full ownership of the program to Kyowa Kirin as a portfolio decision to focus resources on other late-stage programs.

    ChemoCentryxacquisition

    Amgen acquired TAVNEOS from ChemoCentryx in 2022 after it had been on the market for a year.

    Risks & headwinds

    8
    Prolia sales erosion2026

    accelerated sales erosion

    Otezla sales erosion2026

    sales erosion

    TAVNEOS regulatory uncertainty

    FDA requested voluntary withdrawal on January 16, 2026, due to concerns over re-adjudication of primary endpoint results for 9 patients

    Mitigation: Engaged in ongoing dialogue with FDA.

    Denosumab biosimilar competition2026

    anticipated declines

    Price declines for certain products2026

    price declines

    Increased 340B program utilization2026

    continued increases

    Seasonal headwinds to Q1 salesQ1 2026

    lower mid-single-digit year-over-year growth for total company revenues in Q1 2026

    Mitigation: Anticipated and factored into guidance.

    Inventory build impact on Q1 salesQ1 2026

    ~$250 million of inventory build in Q4 2025 could potentially impact Q1 2026 sales

    Mitigation: Anticipated and factored into guidance.

    Q&A highlights

    10

    How does Amgen view the overall obesity portfolio, especially with MariTide, given competitors' focus on combinations and monthly dosing?

    Jay Bradner highlighted MariTide's broad development across multiple indications and mentioned an internal clinical-stage asset, AMG 513, with an undisclosed mechanism, as well as preclinical programs. Robert Bradway emphasized Amgen's intent to compete broadly in the obesity field.

    Internally, we have another clinical stage asset, called AMG 513. We have yet to disclose the mechanism of that medicine, it is progressing in Phase I clinical investigation.

    asked by Michael Yee · answered by James Bradner

    3 min read7 chapters

    Detailed Narrative

    01

    MariTide Clinical Development Progress

    The MariTide Phase III program is rapidly advancing, with chronic weight management studies fully enrolled and ASCVD and heart failure outcome studies progressing well. Amgen has initiated two Phase III sleep apnea studies, bringing the total to six global Phase III studies. Results from completed Phase II chronic weight management and type 2 diabetes studies further increase confidence in MariTide's potential for obesity and related conditions, offering strong efficacy and favorable tolerability with monthly or less frequent dosing.

    02

    Repatha Landmark VESALIUS-CV Trial Results

    Full results from the Phase III VESALIUS-CV trial for Repatha were presented, demonstrating a 25% relative risk reduction in the composite of coronary heart disease death, heart attack, or ischemic stroke, and a 36% reduction in heart attack. These data, observed in over 12,000 patients without prior events over ~4.5 years, reinforce Repatha's role in earlier and intensive LDL-cholesterol management for both primary and secondary prevention, with no new safety signals observed.

    03

    UPLIZNA Regulatory Approvals and Pipeline Expansion

    UPLIZNA received European Commission approval for IgG4-related disease in November 2025 and FDA approval for generalized myasthenia gravis in December 2025. These approvals are supported by strong Phase III data showing durable efficacy and a steroid-sparing benefit with twice-yearly dosing. Amgen plans to initiate two pivotal studies in 2026 for autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy (CIDP), leveraging UPLIZNA's CD19-directed B-cell depletion mechanism.

    04

    Oncology Portfolio and Pipeline Updates

    Amgen's innovative oncology portfolio grew 11% in 2025, driven by BiTE medicines like IMDELLTRA, which received full FDA approval for extensive-stage small cell lung cancer and is becoming a standard of care. BLINCYTO also saw significant growth, up 28% to over $1.5 billion. The company is advancing IMDELLTRA in combination therapy for front-line extensive-stage small cell and in a Phase III study for limited-stage small cell lung cancer, alongside xaluritamig in prostate cancer and Ewing sarcoma.

    05

    Biosimilars Portfolio Growth and Future Wave

    The biosimilars portfolio contributed over $13 billion in sales since 2018, with 2025 sales reaching $3 billion, a 37% increase. PAVBLU, a biosimilar to EYLEA, gained momentum with $700 million in sales in 2025. Amgen is preparing for the next wave of biosimilar launches, with ABP 206 (Opdivo biosimilar) and ABP 234 (Keytruda biosimilar) having completed enrollment in their comparative clinical studies.

    06

    Portfolio Prioritization and Asset Decisions

    Amgen made portfolio decisions to focus resources on late-stage programs, terminating the rocatinlimab development and commercialization collaboration with Kyowa Kirin. Additionally, the company decided not to pursue regulatory approval for bemarituzumab in first-line gastric cancer, despite observing an emerging signal of putative survival benefit in a biomarker-defined patient subset, as overall efficacy did not meet expectations.

    07

    TAVNEOS Regulatory Dialogue and Daxdilimab Phase II Data

    Amgen is engaged in ongoing dialogue with the FDA regarding TAVNEOS following a voluntary withdrawal request on January 16, 2026, related to concerns over re-adjudication of primary endpoint results for 9 patients in the ADVOCATE study. Separately, positive Phase II data for daxdilimab in primary discoid lupus erythematosus were announced, meeting primary and key secondary endpoints with an attractive safety profile, prompting advancement to the next phase of development.

    AI-generated summary of the company’s earnings call. Not investment advice.